Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies
if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the
same subfield and year (this is the minimum needed to enter the top 1%, not the average
within it), or reaches the top citation threshold in at least one of its specific research
topics.
Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor
2005512 citationsDagmar Kubitza, Michael Becka et al.Clinical Pharmacology & Therapeuticsprofile →
Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939—an oral, direct Factor Xa inhibitor—after multiple dosing in healthy male subjects
2005507 citationsDagmar Kubitza, Michael Becka et al.European Journal of Clinical Pharmacologyprofile →
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late)
cites ·
hero ref
This map shows the geographic impact of Barbara Voith's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Barbara Voith with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Barbara Voith more than expected).
This network shows the impact of papers produced by Barbara Voith. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Barbara Voith. The network helps show where Barbara Voith may publish in the future.
Co-authorship network of co-authors of Barbara Voith
This figure shows the co-authorship network connecting the top 25 collaborators of Barbara Voith.
A scholar is included among the top collaborators of Barbara Voith based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with Barbara Voith. Barbara Voith is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
Kubitza, Dagmar, Michael Becka, Barbara Voith, Michael Zuehlsdorf, & Georg Wensing. (2005). Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clinical Pharmacology & Therapeutics. 78(4). 412–421.512 indexed citations breakdown →
6.
Kubitza, Dagmar, Michael Becka, Georg Wensing, Barbara Voith, & Michael Zuehlsdorf. (2005). Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939—an oral, direct Factor Xa inhibitor—after multiple dosing in healthy male subjects. European Journal of Clinical Pharmacology. 61(12). 873–880.507 indexed citations breakdown →
7.
Kubitza, Dagmar, Michael Becka, Georg Wensing, Barbara Voith, & Michael Zuehlsdorf. (2003). Multiple dose escalation study investigating the pharmacodynamics, safety, and pharmacokinetics of BAY 59-7939 an oral, direct Factor Xa inhibitor in healthy male subjects. Blood. 102(11). 811.19 indexed citations
8.
Schmidt, André P., Barbara Voith, & A. Dalhoff. (2001). No evidence of active metabolites of faropenem. 41. 23.1 indexed citations
Voith, Barbara, et al.. (2000). Safety, tolerability, and pharmacokinetics following multiple oral doses of faropenem daloxate and impact on fecal and oral flora. 40. 15.3 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.